Dr. Sandeep Singhal Joins BioMaark Scientific Advisory Team

Vancouver, British Columbia – (October 2nd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise in clinical trial design, deep analytical data support and integration. His experience is vitally important in validating, improving robustness of our assay(s) and integrating a multi perspective of Omics as a clinical diagnostic tool. His capabilities to develop and implement custom bioinformatics programming solutions in collaboration with labs will be an important asset for BioMark. Dr. Singhal’s contributions will enhance our analytical bench strength as we commence commercialization of our assays which is powered by genomics, metabolomics and big data”.

Leveraging big data from genomics, proteomics and metabolomics (Omics) and incorporating smarter analytics to BioMark’s technology platform will improve the overall performance of the tests significantly. Offering a unified view of these disciplines will lead to better diagnostics tools available to better manage cancer treatment at large says”, Dr. Singhal.

 

About Dr. Sandeep Singhal

Dr. Singhal has over 14 years of experience as a Bioinformatician in India, Belgium, USA and Canada with a strong background in cancer genomics, omic-data integration, modeling, algorithm development, statistical analysis and application implementation. He has published extensively in leading scientific journals such as Nature Genetics, Journal of Clinical Oncology, EMNO molecular medicine. He is an editorial board member of Journal of Current Trends in Translational and Research. Dr Singhal holds Ph.D. in Bioinformatics, from Jules Bordet Institute, Universite libre de Bruxelles (ULB) Bruxelles, Belgium and is currently a Research Scientist at Columbia University, New York where his research focus is to understand the role of metabolism and transcriptional cross talk between epigenetic co-regulators and hormones receptor-mediated signalling pathways in both enhancer function and promoter targeted mechanism of gene control.

Dr. Singhal completed his postdoctoral fellowship at Department of Biomedical Informatics, University of Pittsburgh, & The Hamner Institutes for Health Sciences, North Carolina, USA and University of Alberta Canada.

Press Release – Dr. Sandeep Singhal Joins BioMark Scientific Advisory Team

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.